REFERENCES:

Aardex ltd. (2007) Zug Switzerland. Available at: http://www.aardex.ch, accessed on March 24, 2007.

Blomberg B, Spinaci S, Fourie B, Laing R. (2001) The rationale for
recommending fixed-dose combination tablets for treatment of tuberculosis.  
Bull World Health Organ 79, 61-68.  

Certus International Inc. (2007) Chesterfield, Missouri, USA. Available at: http://www.certusintl.com/services_compliance.htm, accessed on March 24 2007.

Connolly C, Davies GR, Wilkinson D. (1999) Who fails to complete treatment? Temporal trends and risk factors for treatment interruption in a community-based directly observed therapy programme in a rural district of South Africa.  Int J Tuberc Lung Dis 3, 1081-1087.  

Cypak Inc. (2007) Stockholm, Sweden. Available at: http://www.cypak.com/index.php?a=products&b=ipp&page=products_ipp, accessed on March 24, 2007.

Davies GR, Pillay M, Sturm AW, Wilkinson D. (1999) Emergence of multidrug-resistant tuberculosis in a community-based directly observed programme in rural South Africa.  Int J Tuberc Lung Dis 3, 795-804

Frieden T, Sbarbaro JA. (2002) The slippery slope to sloppy DOTS.  Int J Tuberc Lung Dis 6, 371- 372.

Information Mediary Inc. ((2007) Ottawa, Ontario, Canada. Available at: http://www.informationmediary.com/index.shtml, accessed on March 24 2007,

Khan MA, Walley JD, Witter SN, Imran A, Safdar N. (2002) Costs and cost effectiveness of different DOT strategies for the treatment of tuberculosis in Pakistan. Health Policy Plan 17, 178-186.   

Kironde S, Klaasen S. (2002) What motivates lay volunteers in high burden, but resource-limited tuberculosis control programs?  Perceptions from the Northern Cape province of South Africa. Int J Tuberc Lung Dis 6, 104-110.  

Li J, Munsiff SS, Driver CR, Sackoff J. (2005) Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000. Clin Infect Dis 41, 83-91.

Lienhardt C, Ogden JA. (2004).Tuberculosis control in resource-poor countries: have we reached the limits of the universal paradigm? Trop Med Int Health 9, 833-41.

Lonnroth K, Lambregts K, Nhien DT, Quy HT, Diwan VK. (2000) Private pharmacies and tuberculosis control: a survey of case detection skills and reported anti-tuberculosis drug dispensing in private pharmacies in Ho Chi Minh City, Vietnam. Int J Tuberc Lung Dis 4, 1052-1059.  

Lonnroth K, Uplekar M, Arora VK et al. (2004) Public-private mix for DOTS implementation: what makes it work? Bull World Health Organ 82, 580-586.

Meijnen S, Weismuller MM, Claessens NJ, Kwanjana JH, Salaniponi FM, Harries AD. (2002)  Outcome of patients with tuberculosis who transfer between reporting units in Malawi. Int J Tuberc Lung Dis 6, 666-71.

Menzies, D, Dion MJ, Francis D et al. (2005) In closely monitored patients, adherence in the first month predicts completion of therapy for Latent Tuberculosis Infection. Int J Tuberc Lung Dis 9, 1343-1348.

Miller LG, Liu H, Hays RD, Golin CE, Beck CK, Asch SM et al. (2002) How well do clinicians estimate patients' adherence to combination antiretroviral therapy? J Gen Intern Med 17, 1-11.

Moulding TS. (1979A) The unrealized potential of the medication monitor. Clin. Pharmacol Ther 25, 131-136

Moulding TS. (1962) Proposal for a time-recording pill dispenser as a method of studying and supervising the self-administration of drugs. Am Rev Resp Dis 85, 754-757.

Moulding T, Knight SJ Jr, Colson JB. (1967) Vertical pill-calendar dispenser and medication monitor for improving the self-administration of drugs. Tubercle 48, 32-37.

Moulding T. (1979B) The Medication Monitor for Treating Tuberculosis in the Developing Countries. Trop Doct 9, 106-109.

Moulding TS, Ellis D. (2007) Compliance Monitors: Status of Development and Potential For Expanding Effective TB Treatment Programs. Available at: http://www.medicationmonitors.net.  accessed April 18, 2007

Moulding T, Onstad GD, Sbarbaro JA. (1970) Supervision of outpatient drug therapy with the medication monitor. Ann Intern Med 73, 559-564.

Moulding TS, Caymittes M. (2002) Managing medication compliance of tuberculosis patients in Haiti with medication monitors. Int J Tuberc Lung Dis 6. 313-319.

Moulding TS, Le HQ, Rikleen D, Davidson P. (2004)  Preventing drug-resistant tuberculosis with a fixed dose combination of isoniazid and rifampin.  Int J Tuberc Lung Dis 8, 743-748.

Nettles RE, Mazo D, Alwood K et al. (2004) Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use. Clin Infect Dis 38, 731-6

Newell JN, Baral SC, Pande SB, Bam DS, Malla P. (2006)  Family-member DOTS and community DOTS for tuberculosis control in Nepal: cluster-randomised controlled trial. Lancet 367, 903-909.

Paterson DL, Swindells S, Mohr J et al. (2000) Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV infections. Ann Intern Med 133, 21-30.

Pungrassami P, Johnson SP, Chongsuvivatwong V et al. (2002) Practice of directly observed treatment (DOT) for tuberculosis in southern Thailand: comparison between different types of DOT observers.  Int J Tuberc Lung Dis; 6 389-395.

Raviglione MC, Pio A. (2002) Evolution of WHO policies for tuberculosis control, 1948-2001. Lancet. 359, 775-780.

Raviglione MC, Smith IM. (2007) XDR tuberculosis--implications for global public health. N Engl J Med. 15, 656-9.

Rusen ID, Aid-Khalid N, Alarcon E (2007) Cochrane systematic review of directly observed therapy for treating tuberculosis- good analysis of the wrong outcome.  Int J Tuberc Lung Dis 11, 120-121.

Saltini C. (2006) Schedule or Dosage?: The Need to Perfect Intermittent Regimens for Tuberculosis  Am. J. Respir. Crit. Care Med 174, 1067-1068,

Simpill Inc. (2007) CapeTown, South Africa. Available at:: http://www.on-cue.co.za/, accessed on March 24, 2007.

Sumartojo E. (1993) When tuberculosis treatment fails. A social behavioral account of patient adherence. Am Rev Respir Dis 147, 1311-20.

Thiam S , LeFevre AM , Hane F  et al. (2007) Effectiveness of a strategy to improve adherence to tuberculosis treatment in a resource-poor setting: a cluster randomized controlled trial. JAMA 297, 380-6

Thomas A, Gopi PG, Santha T et al. (2005) Predictors of relapse among pulmonary tuberculosis patients treated in a DOTS programme in South India. Int J Tuberc Lung Dis  9, 556-61.

Tuberculosis Coalition for Technical Assistance. (2006) International Standards for Tuberculosis Care (ISTC). The Hague: Tuberculosis Coalition for Technical Assistance.

Uplekar M, Pathania V, Raviglione M. (2001) Private practitioners and public health: weak links in tuberculosis control. Lancet 2001 358, 912-916.  

Volmink J, Garner P. (2006) Directly observed therapy for treating tuberculosis. Cochrane Database Syst Rev. Apr 19; (2): CD003343.

Walley JD, Khan MA, Newell JN, Khan MH. (2001) Effectiveness of the direct observation component of DOTS for tuberculosis: a randomized controlled trial in Pakistan. Lancet 357, 664-669.

WHO. (2006) The STOP TB Strategy. WHO/HTM/STB/2006.37   

WHO. (1994) Global Tuberculosis Programme: Framework for Effective TB Control. Geneva: WHO. WHO/TB/94.179  

WHO. ( 2007) Global Tuberculosis Control: Surveillance, Planning, Financing: WHO Report. WHO/HTM/TB/2007/376

WHO. (2003A) Treatment of Tuberculosis: guidelines for national programmes.- third edition. Geneva: WHO. WHO/CDS/TB/2003.313  

WHO Geneva. (2003B) Community Contribution to TB Care Practice and Policy  WHO/CDS/TB/2003.312  

Zwarenstein M, Schoeman JH, Vundule C. Lombard CJ, Tatley M. (1998) Randomized controlled trial of self-supervised and directly observed treatment of tuberculosis. Lancet 352, 1340-43.

Zwarenstein M, Schoeman JH. Vundule C, Lombard CJ, Tatley (2000) M. A randomised controlled trial of lay health workers as direct observers for treatment of tuberculosis. Int J Tuberc Lung Dis 4, 550-554.  
______________________________________________

SUMMARY

I. INTRODUCTION

II. THE SUCCESS AND PROBLEMS WITH DOT

III. RELIABLE PATIENTS - A POTENTIAL RESOURCE FOR REDUCING THE ADHERENCE PROBLEM

IV. DETERMINING THE ADHERENCE OF PATIENTS

V. EXPERIENCE WITH SELF ADMINISTERED TREATMENT GIVEN IN MEDICATION MONITORS (MONITORED SAT)

VI. PROPOSED SUPERVISION OF TREATMENT BASED ON MONITORED SAT AND DOT GIVEN SELECTIVELY

VII. USE OF MONITORED SAT TO IMPROVE TREATMENT OUTCOMES AND EXPAND SERVICES IN VARIOUS SETTINGS

VIII. CAN MEDICATION MONITORS HELP PREVENT DRUG RESISTANT DISEASE

IX) USE OF MEDICATION MONITORS WHEN MANAGING HIV/AIDS and HIV/AIDS/TB

X) EXPENSE AND PRACTICALITY OF USING MEDICATION MONITORS

XI. EVALUATION

XII. IN SUM

REFERENCES

ELECTRONIC MEDICATION MONITORS HOME